EUVIMEDEUVIMED entdecken
Crossref

Incidence of cardiovascular events with fluoropyrimidines in gastrointestinal cancers

Swapnil Nirankari, Anuprita D Daddi, Prabhat Ghanshyam Bhargava, Vikas Ostwal, Anant Ramaswamy

South Asian Journal of Cancer · 18.05.2026 · 15 · 83-87

DOI: 10.25259/sajc_40_2025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift South Asian Journal of Cancer, online erschienen am 18.05.2026. Verfasst von Swapnil Nirankari und 4 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

There is limited data comparing the incidences of cardiac toxicities with fluoropyrimidines (FP) in patients with gastrointestinal cancers (GI). Material and Methods: Patients with GI cancers treated with infusional 5 FU (IFL), capecitabine (C) and S1 between January 2023 and December 2023 were retrieved from a prospectively maintained database at Tata Memorial Hospital (TMH) in Mumbai. Baseline demographic and clinical variables were evaluated. The primary endpoint of the study was estimation of all cardiac events in the study period and calculation of odds ratio (OR) for the relationship between baseline variables and the occurrence of all cardiac events. Major cardiac toxicities, was defined as cardiac abnormalities excluding asymptomatic self-limiting bradycardia or tachycardia.

Results

A total of 2470 patients satisfied the inclusion criteria of the study, of whom 1342 patients (54%) received 5FU, 1071 received Cape (43%) and 55 received S1 (2%). Forty patients (1.6%) experienced a cardiac event, with the most common events being self-limiting bradycardia or tachycardia (15 events, 38%). The incidence of major cardiac toxicities was 1%. There were no differences in incidence of major cardiac events with IFL or C (1% each). The presence of hypertension [ 1.7% vs. 0.8%; OR - 2.27 (0.97–5.26) p = 0.06], diabetes mellitus [ 1.7% vs. 0.8%; OR - 2.38 (1.00–5.26), p = 0.051] and baseline cardiac dysfunction [ 3.1% vs. 0.9%; OR - 3.45 (1.00–11.1) p = 0.071] approached, but did not achieve statistical significance for the occurrence of major cardiac events.

Conclusion

The incidence of cardiac abnormalities appears to be similar between IFL and capecitabine in patients with GI cancers. Cardiovascular comorbidities appeared to have weak correlation with the incidence of FP induced major cardiac events, highlighting the need for further research in this area of unmet need.

Zitieren

APA

Nirankari, S., Daddi, A. D., Bhargava, P. G., Ostwal, V., & Ramaswamy, A. (2026). Incidence of cardiovascular events with fluoropyrimidines in gastrointestinal cancers. South Asian Journal of Cancer, 15, 83-87. https://doi.org/10.25259/sajc_40_2025

Vancouver

Nirankari S, Daddi AD, Bhargava PG, Ostwal V, Ramaswamy A. Incidence of cardiovascular events with fluoropyrimidines in gastrointestinal cancers. South Asian Journal of Cancer. 2026;15:83-87. doi:10.25259/sajc_40_2025

BibTeX
@article{Nirankari2026,
  author = {Nirankari, Swapnil and Daddi, Anuprita D and Bhargava, Prabhat Ghanshyam and Ostwal, Vikas and Ramaswamy, Anant},
  title = {Incidence of cardiovascular events with fluoropyrimidines in gastrointestinal cancers},
  journal = {South Asian Journal of Cancer},
  year = {2026},
  volume = {15},
  pages = {83--87},
  doi = {10.25259/sajc_40_2025}
}
Kostenlos starten →